Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center.
biliary tract cancer
cholangiocarcinoma
follow-up
recurrence
surveillance
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
19 07 2022
19 07 2022
Historique:
received:
09
06
2022
revised:
08
07
2022
accepted:
16
07
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
The aim of this research was to assess the impact of an intensive follow-up program on BTC patients who had received surgery with curative intent at a tertiary referral hospital. BTC patients were followed-up every three months during the first two years after their first surgery and every six months from the third to the fifth post-operative year. A total of 278 BTC patients who received R0/R1 surgery were included. A total of 17.7% of patients underwent a second surgery following disease relapse, and none of these patients experienced additional disease relapse. An intensive follow-up after surgical resection may help in the early identification of disease relapse, leading to early treatment and prolonged survival in selected cases.
Identifiants
pubmed: 35877262
pii: curroncol29070402
doi: 10.3390/curroncol29070402
pmc: PMC9322137
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5084-5090Références
Cancer Treat Rev. 2009 Jun;35(4):322-7
pubmed: 19147294
Hepatology. 2019 Apr;69(4):1803-1815
pubmed: 30251463
Liver Int. 2017 Dec;37(12):1852-1860
pubmed: 28695669
Cancer Treat Rev. 2020 Mar;84:101936
pubmed: 31986437
Ann Oncol. 2016 Sep;27(suppl 5):v28-v37
pubmed: 27664259
Nat Rev Clin Oncol. 2018 Feb;15(2):95-111
pubmed: 28994423
Curr Opin Oncol. 2020 Jul;32(4):364-369
pubmed: 32541326
Cancers (Basel). 2022 May 12;14(10):
pubmed: 35625993
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):547-554
pubmed: 33571059
Gastroenterology. 2013 Dec;145(6):1215-29
pubmed: 24140396
Surg Clin North Am. 2019 Apr;99(2):315-335
pubmed: 30846037
Oncologist. 2016 May;21(5):594-9
pubmed: 27000463
Liver Int. 2019 May;39 Suppl 1:98-107
pubmed: 30831002
Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80
pubmed: 27095655
Am Soc Clin Oncol Educ Book. 2016;35:e194-203
pubmed: 27249723
J Natl Compr Canc Netw. 2018 Apr;16(4):370-376
pubmed: 29632056
World J Surg. 2020 Jan;44(1):232-240
pubmed: 31605170
Liver Int. 2019 May;39 Suppl 1:7-18
pubmed: 30882996
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):483-485
pubmed: 33307876
Ann Surg. 2007 May;245(5):755-62
pubmed: 17457168
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588
pubmed: 32606456
Ann Hepatol. 2017 Jan-Feb 2017;16(1):133-139
pubmed: 28051802
HPB (Oxford). 2014 Feb;16(2):157-63
pubmed: 23530978
J Clin Med. 2021 Jun 26;10(13):
pubmed: 34206799
Ann Surg Oncol. 2016 Jan;23(1):235-43
pubmed: 26059651
Cancer Treat Res Commun. 2021;27:100335
pubmed: 33592561
Nat Rev Dis Primers. 2021 Sep 9;7(1):65
pubmed: 34504109
HPB (Oxford). 2011 Nov;13(11):774-82
pubmed: 21999590